Novartis could sell more drugs through direct-to-patient servicenews2025-10-28T10:53:05+00:00October 28th, 2025|Endpoints News|
Cigna says it will end drug rebates as pressure mounts on PBMsnews2025-10-27T18:47:43+00:00October 27th, 2025|Endpoints News|
Cigna says it will end drug rebates as pressure mounts on PBMsnews2025-10-27T18:47:43+00:00October 27th, 2025|Endpoints News|
Organon CEO exits after internal probe over ‘channel stuffing’ to boost salesnews2025-10-27T18:29:50+00:00October 27th, 2025|Endpoints News|
Organon CEO exits after internal probe over ‘channel stuffing’ to boost salesnews2025-10-27T18:29:50+00:00October 27th, 2025|Endpoints News|
Novartis CEO says $12B Avidity deal could have been ‘twice as big’news2025-10-27T14:57:51+00:00October 27th, 2025|Endpoints News|
WuXi AppTec to divest clinical services to focus on manufacturing businessnews2025-10-27T13:42:32+00:00October 27th, 2025|Endpoints News|
Novo ended Akero deal talks before returning for $4.7B MASH acquisitionnews2025-10-27T07:40:11+00:00October 27th, 2025|Endpoints News|
Novartis to buy RNA drugmaker Avidity Biosciences for $12Bnews2025-10-26T17:46:26+00:00October 26th, 2025|Endpoints News|
FDA approves Bayer’s hot flash treatmentnews2025-10-24T20:16:36+00:00October 24th, 2025|Endpoints News|
